AARDVARK THERAPEUTICS, INC. Increase (Decrease) in Prepaid Expense and Other Assets
AARDVARK THERAPEUTICS, INC. (AARD) reported Increase (Decrease) in Prepaid Expense and Other Assets of $187.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-11
- AARDVARK THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$146.00K.
- AARDVARK THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $333.00K, a 92.37% decline year-over-year.
- AARDVARK THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $369.00K, a 29.02% increase year-over-year.
- AARDVARK THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $1.31M.
- AARDVARK THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2025 was $5.96M, a 1346.60% increase from fiscal 2024.
- AARDVARK THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $412.00K.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$146.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $187.00K 10-Q · filed 2026-08-11 | $556.00K derived: sum of 3 quarters · filed 2026-08-11 | $1.87M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $333.00K 10-Q · filed 2026-05-07 | $702.00K derived: sum of 2 quarters · filed 2026-05-07 | $2.02M derived: sum of 3 quarters · filed 2026-05-07 | $1.93M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $369.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $1.68M derived: sum of 2 quarters · filed 2026-03-23 | $1.60M derived: sum of 3 quarters · filed 2026-08-11 | $5.96M 10-K · filed 2026-03-23 |
| 2025-09-30 | $1.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $1.23M derived: sum of 2 quarters · filed 2026-08-11 | $5.59M 10-Q · filed 2025-11-13 | $5.88M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$84.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $4.28M 10-Q · filed 2026-08-11 | $4.56M derived: sum of 3 quarters · filed 2026-08-11 | $4.31M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $4.36M 10-Q · filed 2026-05-07 | $4.65M derived: sum of 2 quarters · filed 2026-05-07 | $4.39M derived: sum of 3 quarters · filed 2026-05-07 | $4.44M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $286.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $32.00K derived: sum of 2 quarters · filed 2026-03-23 | $80.00K derived: sum of 3 quarters · filed 2026-03-23 | $412.00K 10-K · filed 2026-03-23 |
| 2024-09-30 | -$254.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$206.00K derived: sum of 2 quarters · filed 2025-11-13 | $126.00K 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $48.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $380.00K 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | $332.00K 10-Q · filed 2025-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |